Which has higher earnings and valuation, OKYO or AVXL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$4.71M N/A N/A Anavex Life Sciences N/A N/A -$46.38M -$0.46 N/A

Is OKYO or AVXL more profitable?

OKYO Pharma's return on equity of 0.00% beat Anavex Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Anavex Life Sciences N/A -38.76% -35.01%

Which has preferable earnings & valuation, OKYO or AKBA?

OKYO Pharma has higher earnings, but lower revenue than Akebia Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$4.71M N/A N/A Akebia Therapeutics $236.20M 1.06 -$5.34M -$0.08 N/A

Which has better valuation & earnings, TRDA or OKYO?

OKYO Pharma has lower revenue, but higher earnings than Entrada Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entrada Therapeutics $25.42M 9.56 -$143.75M -$3.99 N/A OKYO Pharma N/A N/A -$4.71M N/A N/A

Which has higher valuation & earnings, FBRX or OKYO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.64 N/A OKYO Pharma N/A N/A -$4.71M N/A N/A

Is FBRX or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -106.17% -85.50% OKYO Pharma N/A N/A N/A

Which has preferable valuation and earnings, MGNX or OKYO?

OKYO Pharma has lower revenue, but higher earnings than MacroGenics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MacroGenics $149.50M 1.65 -$74.62M -$1.10 N/A OKYO Pharma N/A N/A -$4.71M N/A N/A

Is MGNX or OKYO more profitable?

OKYO Pharma has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. OKYO Pharma's return on equity of 0.00% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -44.79% -147.80% -28.40% OKYO Pharma N/A N/A N/A

OKYO Pharma (OKYO) Competitors

$1.59 -0.03 (-1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$1.59 0.00 (0.00%)

As of 04:10 PM Eastern

Compare

OKYO vs. AVXL, AKBA, TRDA, FBRX, and MGNX

Should you buy OKYO Pharma stock or one of its competitors? MarketBeat compares OKYO Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OKYO Pharma include Anavex Life Sciences (AVXL), Akebia Therapeutics (AKBA), Entrada Therapeutics (TRDA), Forte Biosciences (FBRX), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry.

How does OKYO Pharma compare to Anavex Life Sciences?

OKYO Pharma (NASDAQ:OKYO) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

OKYO Pharma's return on equity of 0.00% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Anavex Life Sciences	N/A	-38.76%	-35.01%

In the previous week, OKYO Pharma's average media sentiment score of 0.00 equaled Anavex Life Sciences'average media sentiment score.

Company	Overall Sentiment
OKYO Pharma	Neutral
Anavex Life Sciences	Neutral

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

OKYO Pharma currently has a consensus price target of $6.33, indicating a potential upside of 298.32%. Anavex Life Sciences has a consensus price target of $21.33, indicating a potential upside of 714.25%. Given Anavex Life Sciences' higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

OKYO Pharma has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

Summary

OKYO Pharma beats Anavex Life Sciences on 4 of the 7 factors compared between the two stocks.

How does OKYO Pharma compare to Akebia Therapeutics?

OKYO Pharma (NASDAQ:OKYO) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

OKYO Pharma currently has a consensus target price of $6.33, suggesting a potential upside of 298.32%. Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 398.79%. Given Akebia Therapeutics' higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

OKYO Pharma has higher earnings, but lower revenue than Akebia Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
Akebia Therapeutics	$236.20M	1.06	-$5.34M	-$0.08	N/A

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

OKYO Pharma has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. OKYO Pharma's return on equity of 0.00% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

In the previous week, Akebia Therapeutics had 2 more articles in the media than OKYO Pharma. MarketBeat recorded 2 mentions for Akebia Therapeutics and 0 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.00 equaled Akebia Therapeutics'average media sentiment score.

Company	Overall Sentiment
OKYO Pharma	Neutral
Akebia Therapeutics	Neutral

OKYO Pharma has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Summary

OKYO Pharma beats Akebia Therapeutics on 6 of the 11 factors compared between the two stocks.

How does OKYO Pharma compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Entrada Therapeutics had 5 more articles in the media than OKYO Pharma. MarketBeat recorded 5 mentions for Entrada Therapeutics and 0 mentions for OKYO Pharma. Entrada Therapeutics' average media sentiment score of 0.22 beat OKYO Pharma's score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Entrada Therapeutics	Neutral
OKYO Pharma	Neutral

OKYO Pharma has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. OKYO Pharma's return on equity of 0.00% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
OKYO Pharma	N/A	N/A	N/A

Entrada Therapeutics has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market.

Entrada Therapeutics presently has a consensus price target of $17.50, suggesting a potential upside of 179.55%. OKYO Pharma has a consensus price target of $6.33, suggesting a potential upside of 298.32%. Given OKYO Pharma's stronger consensus rating and higher possible upside, analysts plainly believe OKYO Pharma is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

OKYO Pharma has lower revenue, but higher earnings than Entrada Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	9.56	-$143.75M	-$3.99	N/A
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A

Summary

OKYO Pharma beats Entrada Therapeutics on 8 of the 12 factors compared between the two stocks.

How does OKYO Pharma compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

OKYO Pharma's return on equity of 0.00% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
OKYO Pharma	N/A	N/A	N/A

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A

Forte Biosciences has a beta of 2.87, indicating that its stock price is 187% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market.

Forte Biosciences currently has a consensus price target of $67.00, indicating a potential upside of 327.57%. OKYO Pharma has a consensus price target of $6.33, indicating a potential upside of 298.32%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Forte Biosciences is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Forte Biosciences' average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score.

Company	Overall Sentiment
Forte Biosciences	Neutral
OKYO Pharma	Neutral

Summary

Forte Biosciences and OKYO Pharma tied by winning 4 of the 8 factors compared between the two stocks.

How does OKYO Pharma compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

MacroGenics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market.

OKYO Pharma has lower revenue, but higher earnings than MacroGenics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.65	-$74.62M	-$1.10	N/A
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A

MacroGenics currently has a consensus price target of $5.50, suggesting a potential upside of 41.75%. OKYO Pharma has a consensus price target of $6.33, suggesting a potential upside of 298.32%. Given OKYO Pharma's stronger consensus rating and higher possible upside, analysts clearly believe OKYO Pharma is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, MacroGenics had 3 more articles in the media than OKYO Pharma. MarketBeat recorded 3 mentions for MacroGenics and 0 mentions for OKYO Pharma. MacroGenics' average media sentiment score of 0.49 beat OKYO Pharma's score of 0.00 indicating that MacroGenics is being referred to more favorably in the media.

Company	Overall Sentiment
MacroGenics	Neutral
OKYO Pharma	Neutral

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

OKYO Pharma has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. OKYO Pharma's return on equity of 0.00% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
OKYO Pharma	N/A	N/A	N/A

Summary

OKYO Pharma beats MacroGenics on 7 of the 12 factors compared between the two stocks.

Get OKYO Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKYO vs. The Competition

Export

Metric	OKYO Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$65.70M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	N/A	18.61	23.92	23.74
Price / Sales	N/A	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	-9.94	8.04	10.28	6.78
Net Income	-$4.71M	$23.89M	$3.57B	$337.51M
7 Day Performance	-7.02%	-5.97%	-1.43%	-2.72%
1 Month Performance	-2.45%	2.78%	3.27%	1.87%
1 Year Performance	-16.32%	36.26%	23.37%	26.60%

OKYO Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKYO OKYO Pharma	2.2315 of 5 stars	$1.59 -1.9%	$6.33 +298.3%	-14.7%	$65.70M	N/A	N/A	7
AVXL Anavex Life Sciences	1.4991 of 5 stars	$2.79 -6.4%	$21.33 +664.6%	-68.9%	$276.16M	N/A	N/A	40	Upcoming Earnings High Trading Volume
AKBA Akebia Therapeutics	1.6738 of 5 stars	$0.94 -8.2%	$4.67 +398.4%	-76.4%	$273.62M	$236.20M	N/A	430
TRDA Entrada Therapeutics	3.9131 of 5 stars	$6.64 -3.9%	$18.25 +174.8%	-23.4%	$268.25M	$5.74M	N/A	110	Analyst Forecast
FBRX Forte Biosciences	1.3989 of 5 stars	$18.17 -5.6%	$67.00 +268.7%	+45.9%	$267.16M	N/A	N/A	5

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKYO) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OKYO Pharma (OKYO) Competitors

OKYO vs. AVXL, AKBA, TRDA, FBRX, and MGNX

How does OKYO Pharma compare to Anavex Life Sciences?

Summary

How does OKYO Pharma compare to Akebia Therapeutics?

Summary

How does OKYO Pharma compare to Entrada Therapeutics?

Summary

How does OKYO Pharma compare to Forte Biosciences?

Summary

How does OKYO Pharma compare to MacroGenics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO vs. The Competition

OKYO Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OKYO Pharma (OKYO) Competitors

OKYO vs. AVXL, AKBA, TRDA, FBRX, and MGNX

How does OKYO Pharma compare to Anavex Life Sciences?

Is OKYO or AVXL more profitable?

Does the media prefer OKYO or AVXL?

Do institutionals & insiders believe in OKYO or AVXL?

Do analysts recommend OKYO or AVXL?

Which has more risk and volatility, OKYO or AVXL?

Which has higher earnings and valuation, OKYO or AVXL?

Summary

How does OKYO Pharma compare to Akebia Therapeutics?

Do analysts rate OKYO or AKBA?

Which has preferable earnings & valuation, OKYO or AKBA?

Do insiders and institutionals hold more shares of OKYO or AKBA?

Is OKYO or AKBA more profitable?

Does the media refer more to OKYO or AKBA?

Which has more volatility and risk, OKYO or AKBA?

Summary

How does OKYO Pharma compare to Entrada Therapeutics?

Does the media favor TRDA or OKYO?

Is TRDA or OKYO more profitable?

Which has more volatility and risk, TRDA or OKYO?

Do analysts prefer TRDA or OKYO?

Do institutionals and insiders have more ownership in TRDA or OKYO?

Which has better valuation & earnings, TRDA or OKYO?

Summary

How does OKYO Pharma compare to Forte Biosciences?

Is FBRX or OKYO more profitable?

Do insiders & institutionals believe in FBRX or OKYO?

Which has higher valuation & earnings, FBRX or OKYO?

Which has more risk & volatility, FBRX or OKYO?

Do analysts recommend FBRX or OKYO?

Does the media favor FBRX or OKYO?

Summary

How does OKYO Pharma compare to MacroGenics?

Which has more risk & volatility, MGNX or OKYO?

Which has preferable valuation and earnings, MGNX or OKYO?

Do analysts rate MGNX or OKYO?

Does the media prefer MGNX or OKYO?

Do insiders and institutionals hold more shares of MGNX or OKYO?

Is MGNX or OKYO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO vs. The Competition

OKYO Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools